amryt-logo.png
Amryt Announces the Appointment of Sheila Frame as President Americas
April 06, 2021 02:00 ET | Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, April 6, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...
amryt-logo.png
Amryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
March 31, 2021 02:00 ET | Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...
amryt-logo.png
Amryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
March 30, 2021 02:00 ET | Amryt Pharma plc
DUBLIN, Ireland, and Boston MA, March 30, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel...
amryt-logo.png
Amryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
March 29, 2021 02:00 ET | Amryt Pharma plc
  DUBLIN, Ireland, and Boston MA, March 29, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing...
amryt-logo.png
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
March 23, 2021 03:00 ET | Amryt Pharma plc
Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy DUBLIN, Ireland, and Boston MA, March 23, 2021, Amryt (Nasdaq: AMYT,...
amryt-logo.png
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
March 22, 2021 03:00 ET | Amryt Pharma plc
Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin) DUBLIN, Ireland, and Boston MA, March 22, 2021, Amryt (Nasdaq: AMYT, AIM:...
amryt-logo.png
Director/PDMR Shareholding
March 15, 2021 06:00 ET | Amryt Pharma plc
Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the...
amryt-logo.png
Exercise of Options and Total Voting Rights
March 12, 2021 02:00 ET | Amryt Pharma plc
Exercise of Options and Total Voting Rights DUBLIN, Ireland, and Boston MA, March 12, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...
amryt-logo.png
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
March 11, 2021 06:30 ET | Amryt Pharma plc
Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights DUBLIN, Ireland, and Boston MA, March 11, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage...
amryt-logo.png
Director/PDMR Shareholding
March 08, 2021 13:00 ET | Amryt Pharma plc
Grant of Options and Notification of Transactions by Persons Discharging Managerial Responsibilities DUBLIN, Ireland, and Boston MA, March 8, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global,...